Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.31 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.31 |
| ▸ | PRKCI | P41743 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921699 | 0.79 | PRKCI (0.42) | TTBK1TTBK2PRKCIAXLKDM4E | |
| SCHEMBL12833213 | 0.68 | EGLN1 (0.38) | TTBK1TTBK2KDM4EMAPT | |
| SCHEMBL9918659 | 0.68 | TTBK1 (0.31) | TTBK1TTBK2PRKCIAXL | |
| SCHEMBL3492520 | 0.67 | JAK2 (0.47) | TTBK1TTBK2 | |
| SCHEMBL9918666 | 0.67 | JAK3 (0.38) | TTBK1TTBK2 | |
| SCHEMBL12684548 | 0.65 | NUDT1 (0.33) | TTBK1TTBK2 | |
| SCHEMBL23647524 | 0.64 | PRKCI (0.38) | TTBK1TTBK2PRKCIAXLKDM4E | |
| SCHEMBL9918753 | 0.63 | PRKCI (0.35) | TTBK1TTBK2PRKCIAXLKDM4E | |
| SCHEMBL20431216 | 0.62 | ADORA1 (0.38) | KDM4EALDH1A1GAAKMT2A | |
| SCHEMBL1504315 | 0.62 | PRKCI (0.35) | TTBK1TTBK2PRKCIAXLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012106448-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | TTBK1 597/4885TTBK2 854/4885PRKCI 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.